Boehringer raises hope of oral drug for diabetic eye disease Boehringer has started a phase 2 trial of an oral therapy that could help people with diabetic macular oedema avoid regular injections into the eye.

#Ophthalmology #BoehringerIngelheim #diabeticeyedisease #diabeticmacularoedema #DME #BI1815368 #THULITEstudy #centreinvolvedDME #VEGFtargetingdrugs #Roche #Vabysmo #faricimab #Lucentis #ranibizumab #Bayer #Regeneron #Eylea #aflibercept #Susvimo #ranibizumab
pharmaphorum.com/news/boehrin...

Roche's Susvimo Receives FDA Approval for Diabetic Macular Edema, A Game Changer in Eye Health Roche's Susvimo has achieved FDA approval to treat diabetic macular edema, a significant advancement in eye health for diabetics. This approval underscores the growing landscape of innovative therapies for vision-related conditions.

Roche's Susvimo Receives FDA Approval for Diabetic Macular Edema, A Game Changer in Eye Health #USA #Las_Vegas #DME #Susvimo #Diabetic_Macular_Edema

FDA Approves Susvimo for Diabetic Macular Edema - Drugs.com MedNews The U.S. Food and Drug Administration has approved Susvimo (ranibizumab) 100 mg mL for treating diabetic macular edema. Susvimo is the first and only FDA-approv

FDA approves #Susvimo implant for diabetic macular edema - first continuous-delivery eye treatment via one-time surgical implant, refilled every 6 months. Phase 3 trial shows equal vision improvement vs monthly injections. Common side effects: eye bleeding, pain, floaters.